Cargando…

Association of Antibiotics and Other Drugs with Clinical Outcomes in Metastatic Melanoma Patients Treated with Immunotherapy

Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have improved survival in many advanced cancers including advanced melanoma, renal cell, urothelial, and non-small-cell lung cancers. However, not all patients respond,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angrish, Manish D., Agha, Arun, Pezo, Rossanna C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324393/ https://www.ncbi.nlm.nih.gov/pubmed/34336290 http://dx.doi.org/10.1155/2021/9120162

Ejemplares similares

Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte–associated protein 4 therapy: A retrospective cohort study
por: Naderi-Azad, Sheida, et al.
Publicado: (2020)

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
por: Adegoke, Nurudeen A, et al.
Publicado: (2023)

Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities
por: Pezo, Rossanna C., et al.
Publicado: (2019)

Regression of pigmented lesions in a patient with metastatic melanoma treated with immunotherapy
por: Schwager, Zachary, et al.
Publicado: (2018)

Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review
por: Komorowski, Adam S., et al.
Publicado: (2020)

Complications of sequential immunotherapy in metastatic melanoma
por: Bufalino, Shams, et al.
Publicado: (2015)

Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
por: Wong, Pok Fai, et al.
Publicado: (2019)

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer
por: Pezo, Rossanna C., et al.
Publicado: (2017)

Current status and perspectives in immunotherapy for metastatic melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2018)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
por: Rauwerdink, Daan Jan Willem, et al.
Publicado: (2020)

Combined Immunotherapy in Metastatic Melanoma with Unknown Primary
por: Khan, Yasir, et al.
Publicado: (2019)

Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline
por: Blanchette, Phillip, et al.
Publicado: (2022)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023)

Identification of a pyroptosis‐based model for predicting clinical outcomes from immunotherapy in patients with metastatic melanoma
por: Wu, Guanghao, et al.
Publicado: (2022)

Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US
por: Moyers, Justin T., et al.
Publicado: (2020)

Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma
por: Mangin, Marie‐Alix, et al.
Publicado: (2021)

Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy
por: Gaffuri, P., et al.
Publicado: (2019)

CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy
por: Mallardo, Domenico, et al.
Publicado: (2023)

Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy
por: Martinez-Morilla, Sandra, et al.
Publicado: (2020)

Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma
por: Costa Svedman, Fernanda, et al.
Publicado: (2022)

Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience
por: Asher, Nethanel, et al.
Publicado: (2021)

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
por: Mignard, Claire, et al.
Publicado: (2018)

Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020)

Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
por: Krimphove, Marieke J., et al.
Publicado: (2019)

A nano-enhanced vaccine for metastatic melanoma immunotherapy
por: Salotto, Katelyn E., et al.
Publicado: (2022)

Electrochemotherapy and Other Clinical Applications of Electroporation for the Targeted Therapy of Metastatic Melanoma
por: Cucu, Corina Ioana, et al.
Publicado: (2021)

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients
por: Vera Aguilera, Jesus, et al.
Publicado: (2020)

Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials
por: Schreiber, Anna R., et al.
Publicado: (2021)

Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?
por: Amaral, Teresa, et al.
Publicado: (2020)

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy
por: Dupuis, Frantz, et al.
Publicado: (2018)

Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors
por: Tonneau, Marion, et al.
Publicado: (2022)

How I treat metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2019)

Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.
por: Thatcher, N., et al.
Publicado: (1977)

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
por: Yu, Chune, et al.
Publicado: (2019)

Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma
por: Biteghe, Fleury Augustin Nsole, et al.
Publicado: (2020)

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
por: Ralli, Massimo, et al.
Publicado: (2020)

The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2021)

Differences in and verification of genetic alterations in chemotherapy and immunotherapy for metastatic melanoma
por: Li, Yang, et al.
Publicado: (2021)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
por: De Risi, Ivana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2vhl5hqsghdjj8ahui53trhprt